Device specific vigilance guidance: Artificial Heart Valves

AI Summary

This regulatory guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) provides instructions for manufacturers regarding post-market surveillance for surgical and transcatheter heart valves. While the document does not target a specific company or detail a single inspection, it applies to all manufacturers operating under the UK regulatory framework, specifically Statutory Instrument SI 2024 No. 1368. The guidance establishes a standardized approach to reporting device performance problems and clinical incidents using International Medical Device Regulators Forum (IMDRF) codes. Key issues identified for mandatory reporting include mechanical failures such as leaflet ruptures, stent fractures, and valve thrombosis, as well as clinical complications like vascular injury or myocardial infarction. For transcatheter heart valves, specific focus is placed on delivery system failures and valve malposition. Manufacturers are required to take specific actions: individual serious incidents must be reported within statutory timescales; periodic summary reports (PSR) may be utilized for certain events if prior agreement is granted; and trend reporting is mandatory when there is a significant increase in the frequency or severity of adverse events. These measures are designed to ensure continuous risk analysis and the ongoing safety of heart valve populations.